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To study the role of mGlu7 receptors (mGluR7), we used ho-
mologous recombination to generate mice lacking this metabo-
tropic receptor subtype (mGluR7/). After the serendipitous
discovery of a sensory stimulus-evoked epileptic phenotype,
we tested two convulsant drugs, pentylenetetrazole (PTZ) and
bicuculline. In animals aged 12 weeks and older, subthreshold
doses of these drugs induced seizures in mGluR7/, but not
in mGluR7/, mice. PTZ-induced seizures were inhibited by
three standard anticonvulsant drugs, but not by the group III
selective mGluR agonist (R,S)-4-phosphonophenylglycine
(PPG). Consistent with the lack of signs of epileptic activity in
the absence of specific stimuli, mGluR7/ mice showed no
major changes in synaptic properties in two slice preparations.
However, slightly increased excitability was evident in hip-
pocampal slices. In addition, there was slower recovery from
frequency facilitation in cortical slices, suggesting a role for
mGluR7 as a frequency-dependent regulator in presynaptic
terminals. Our findings suggest that mGluR7 receptors have a
unique role in regulating neuronal excitability and that these
receptors may be a novel target for the development of anti-
convulsant drugs.
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An imbalance in glutamatergic excitatory neurotransmission and
GABAergic synaptic inhibition in the vertebrate CNS can cause
seizures and may be a major cause of epilepsy. There is, there-
fore, considerable interest in how these neurotransmitter systems
are regulated physiologically. Metabotropic glutamate receptors
(mGluRs) couple to G-proteins and can modulate L-glutamate
release, GABA release, and neuronal excitability (Conn and Pin,
1997). They are subdivided into groups I (mGluR1, mGluR5), II
(mGluR2, mGluR3), and III (mGluR4, mGluR6, mGluR7,
mGluR8) on the basis of homology, intracellular messengers, and
ligand selectivity (Conn and Pin, 1997). mGluR7 is the most
highly conserved member, and its mGluR7a-isoform is distrib-
uted widely throughout the CNS (Kinzie et al., 1995; Ohishi et
al., 1995; Bradley et al., 1996; Brandstaetter et al., 1996; Flor et
al., 1997; Shigemoto et al., 1997). The two isoforms of the recep-
tor are localized presynaptically, close to release sites (Bradley et
al., 1996; Brandstaetter et al., 1996; Shigemoto et al., 1996; Ki-
noshita et al., 1998).
In recombinant expression systems L-2-amino-4-phosphono-
butyrate (L-AP4), L-serine-O-phosphate (L-SOP), and (R,S)-4-
phosphonophenylglycine [(R,S)PPG] activate mGluR7 and its
coupling to adenylate cyclase inhibition (Gasparini et al., 1999).
Among the group III mGluRs, mGluR7 has the lowest affinity for
these group III mGluR selective ligands and the endogenous
ligand L-glutamate (Okamoto et al., 1994; Saugstad et al., 1994;
Flor et al., 1997). In a variety of preparations L-AP4 and L-SOP
reduce excitatory synaptic transmission (Koerner and Cotman,
1981; Davies and Watkins, 1982; Lanthorn et al., 1984; Anson and
Collins, 1987; Bushell et al., 1995; Manzoni and Bockaert, 1995;
Vignes et al., 1995; Pisani et al., 1997) via a putative presynaptic
mechanism (Baskys and Malenka, 1991; Gereau and Conn, 1995)
or via heterosynaptic effects on interneuron terminals (Salt and
Eaton, 1995; Wan and Cahusac, 1995; Cartmell and Schoepp,
2000; Semyanov and Kullmann, 2000).
The notion that group III mGluRs are potential targets for
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novel antiepileptic drugs is supported by results in rodent models
of epilepsy in which group III selective agonists showed pro-
longed anticonvulsant actions [L-AP4, L-SOP (Tizzano et al.,
1995; Tang et al., 1997); (R,S)-PPG (Chapman et al., 1999;
Gasparini et al., 1999); L-SOP (Yip et al., 2001)] and increased
seizure threshold (L-AP4; Suzuki et al., 1999) or seizure latency
(Thomsen and Dalby, 1998). In addition, in epilepsy the changes
have been noted in the agonist sensitivity (Neugebauer et al.,
2000), expression (Aronica et al., 1997; Liu et al., 2000; Yip et al.,
2001), and receptor responses of group III mGluRs (Holmes et
al., 1996; Neugebauer et al., 1997; Dietrich et al., 1999; Klapstein
et al., 1999).
The lack of specific ligands to address mGluR7 function
prompted us to generate mice lacking these receptors. A previous
study that used these animals revealed deficits in taste aversion
and fear responses (Masugi et al., 1999). The present study
describes a role of mGluR7 in epilepsy.
MATERIALS AND METHODS
Generation of mGluR7/ mice
A genomic fragment of the mouse mGluR7 gene was isolated from a
129SV/J FIX phage library (Stratagene, La Jolla, CA) and probed with
a human mGluR7 cDNA. A 2.055 kb NheI–NheI DNA fragment com-
prising the first coding exon was sequenced. It contained 405 bp of
5-untranslated region (UTR; as judged by homology to rat mGluR7
cDNA), followed by codons for the first 164 amino acids of mouse
mGluR7. The targeting vector was constructed by inserting a 0.6 kb
NruI–XhoI DNA fragment (comprising 115 bp of 5-UTR) 5 of the
pMCNeo cassette into a StuI–XhoI cleaved pTV-0 vector that contains
the herpes virus thymidine kinase (TK) gene for negative selection. A 7
kb NheI–NheI DNA fragment comprising genomic sequences down-
stream of the 2.055 kb NheI–NheI fragment was inserted into a NheI site
located between pMCNeo and pMCTK in pTV-0. Proper targeting
resulted in deleting 0.585 kb of the first coding exon and 0.73 kb of the
next intron of the mGlu7 gene. Embryonic day 14 (E14) embryonic stem
(ES) cells [129/Ola; genotype A w (agouti), c ch (albino), p (pink-eyed
dilution)] were transfected with 30 g of NotI-linearized and
dideoxynucleotide-end-filled (using Klenow enzyme) targeting vector by
electroporation (250 V and 500 F; Bio-Rad Gene Pulser, Munich,
Germany). G418 (600 g/ml) and Ganciclovir (Gancv; 2 M) selection
were applied 24 and 48 hr later, respectively. DNA from double-resistant
ES colonies was subjected to PCR analysis by using either one of two
PCR primers matching sequences in the NheI–NruI fragment located just
5 to, but not contained within, the targeting vector (primer-1, 5-
cttctgccagagctgacagtcaaag-3; primer-2, 5-gtcagcaccaatatcgcgactcatc-3)
and either one of two primers located in the neo gene (primer-3,
5-gcgtgcaatccatcttgttcaatgg-3; primer-4, 5-gcgctgacagccggaacacg-3).
Combinations of primer-1 or primer-2 and either one of two primers
matching sequences in the coding region of the first coding exon
(primer-5, 5-gaaagtgagcgactgttcgagcg-3; primer-6, 5-
gatgttggctaccatgatggagaccg-3) served to detect the presence of a wild-
type mGluR7 allele. Two of 112 G418 rGancv r double-resistant ES cell
clones carried a correctly targeted mGluR7 allele, as assessed by PCR
and confirmed by Southern blot analysis of genomic DNA digested with
NheI and NcoI, respectively, and probed with probe A (158 bp NheI–NruI
fragment), probe B (0.6 kb NruI–XhoI fragment), and a neo gene probe
(probe D) (Fig. 1). Southern blot analysis that used a complete mGluR7
cDNA probe (probe D) revealed no additional rearrangements in the
locus (data not shown). Wild-type () and mutant alleles () are
indicated by the presence of a 2 kb () versus 1.8 kb () NheI and a 2.5
kb () versus a 2.3 kb () NcoI DNA fragment when probed with probe
A or B (Fig. 1a,b). The diagnostic sizes for a properly targeted mGluR7
allele when probed with neo (probe D) are 1.8 kb (NheI) and 2.3 kb
(NcoI). Both ES clones were used successfully to produce germ line
chimeras (11 for each clone) by aggregation for 2–3 hr with 10 6 ES cells
per milliliter.
Genotyping
F1 mice carrying a targeted mGluR7 allele were identified by Southern
blot analysis (Fig. 1b). F2 mice, derived from matings of pairs of het-
erozygous parents, were screened by PCR and used pairs of one of three
different forward primers (5-cttctgccagagctgacagtcaaag-3 or 5-
gtcagcaccaatatcgcgactcatc-3 or 5-acagtcaaagatcagactcaggggc-3 or 5-
ctccccataagtcagcaccaatatc-3) and one of two Neo-specific primers
(primer-3 or primer-4) (Fig. 1a) to detect the targeted allele. A combi-
nation of primer-7 (5-gagagatggatagcaagcaagggag-3) and primer-8 (5-
gtgtccctggaacaagtgtccag-3) served to detect the endogenous mGluR7
allele in mGluR7/ and mGluR7/ mice and to confirm its absence in
Figure 1. Targeted disruption of the mouse mGluR7 gene and its mo-
lecular analysis. a, Scheme of mGluR7 genomic DNA, targeting vector,
disrupted gene, probes (stippled bars), and PCR primers (arrows). Neo,
Neomycin resistance gene; TK, herpes virus thymidine kinase gene; Nh,
NheI; Nc, NcoI; Nr, NruI; X, XhoI. b, Southern blot analysis. Shown is the
result of a representative litter of F2 mice obtained by crossing a pair of
mGluR7/ F1 mice. DNA was NheI digested. Probe A was used (as
shown in a). Wild-type and mutant alleles are represented by DNA
fragments of 2.055 and 1.885 kb, respectively. c, PCR genotyping. Exam-
ple of a typical PCR result with the use of tail DNA of mGluR7/,
mGluR7/, and mGluR7/ mice. Primer pairs 1  3 yield a 1.1 kb
product (mutant allele). Primers 7  8 yield a 0.7 kb DNA fragment
(wild-type allele). d, Northern blot analysis. Total RNA was isolated from
mGluR7/, mGluR7/, and mGluR7/ brains. cDNA probes were
APP, mGluR7, mGluR4, and mGluR8. e, f, RT-PCR. mGluR7b-specific
RT-PCR products of expected sizes 2.7 kb (primers 11 10) and 0.092 kb
(primers 9  10) were detected readily with mGluR7/, but not with
mGluR7/, brain RNA as a template.
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mGluR7/ mice. mGluR4 mutant mice were genotyped as described
previously (Pekhletski et al., 1996). mGluR8 (Duvoisin et al., 1995)
mutant mice (R. Duvoisin and C. Zhang, unpublished results) were
genotyped by PCR (hot-start PCR, TaqStart antibody; Promega, Madi-
son, WI) according to the manufacturer’s instructions. Annealing was 45
sec at 68°C; primer extension was at 74°C for 45 sec for 34 cycles. One
combination of two primers (taactaccaggtggacgaactctc; cacaaaggtggtg-
gcaatgattcc) was used to diagnose the endogenous mGluR8 allele in
mGluR8/ and mGluR8/ mice and to confirm its absence in
mGluR8/ mice. Another primer (taatatgcgaagtggacctgggac) combined
with the first one shown above served to detect the targeted allele.
DNA and RNA analysis
Southern and Northern blot analyses, sequencing, PCR, and RT-PCR
were performed according to standard protocols. For Northern blot
analysis the following probes were used: a 3 kb EcoRI fragment of mouse
amyloid precursor protein (APP) cDNA, a 3 kb HindIII fragment of
human mGluR7b cDNA, a 0.57 kb PstI human mGluR4 cDNA fragment
(encoding amino acids 520–710), and a 1.150 kb rat mGluR8 cDNA
probe (encoding amino acids 1–350 of mGluR8). Hybridization with
APP cDNA served as a control for loading equivalent amounts of total
brain RNA in each lane. RT-PCR of mGluR7/ and mGluR7/ brain
RNA was performed with several pairs of oligonucleotide primers, in-
cluding primer-1 and primer-4, primer-1 and primer-10, primer-11 and
primer-10, and primer-9 and primer-10. Primer-9 and primer-10 were
designed specifically to detect sequences comprising exon b (92 bp)
encoding one of two (a and b) C-terminal splice variants of mGluR7
(Flor et al., 1997).
Western blot and immunocytochemical analysis
Immunoblot procedures and immunocytochemistry were as described
previously (Shigemoto et al., 1996, 1997; Kinoshita et al., 1998). Briefly,
for Western blot analysis the crude membrane preparations from mouse
cerebellum, hippocampus, and combined brain regions other than the
cerebellum and hippocampus were separated by 7% SDS-PAGE and
transferred to polyvinylidene difluoride membranes. The membranes
were reacted with an affinity-purified antibody for mGluR7a (Shigemoto
et al., 1996). For detection, an alkaline phosphatase-labeled anti-rabbit
secondary antibody (Chemicon, Temecula, CA) was used. For immuno-
cytochemistry, wild-type and mGluR7/ mice were anesthetized deeply
and perfused transcardially with 3.5% paraformaldehyde, 1% picric acid,
and 0.05% glutaraldehyde in 0.1 M phosphate buffer (PB), pH 7.3. The
brains were removed, cryoprotected (30% sucrose in 0.1 M PB overnight
at 4°C), and cut on a freezing microtome. The 40-m-thick sections were
incubated with antibodies for mGluR7a, mGluR7b, mGluR4a, or
mGluR8a (Shigemoto et al., 1997; Kinoshita et al., 1998) in PBS con-
taining 2% normal goat serum and 0.1% Triton X-100 overnight at 15°C.
After washes in PBS the sections were incubated with biotinylated goat
anti-rabbit or goat anti-guinea pig IgG (Vector Laboratories, Burlin-
game, CA). Then the sections were washed again, reacted with the ABC
kit (Vector Laboratories), and finally incubated with 0.05% diaminoben-
zidine and 0.0006% hydrogen peroxide.
Chromosomal mapping of the mGluR7 gene
A 129 mouse bacterial artificial chromosome (BAC) was identified and
isolated by the PCR screening of a genomic 129SV DNA bank in
pBeloBAC11 (Research Genetics, Huntsville, AL). The PCR primers
were 7 and 8 (Fig. 1). These amplified specifically the first coding exon of
the mGluR7 gene, as confirmed by sequencing. Southern blot analysis
was performed with a mGluR7 cDNA probe to confirm the presence of
unrearranged and diagnostic mGluR7 genomic DNA fragments. For
fluorescent in situ hybridization (FISH), BAC DNA was labeled with
digoxigenin-dUTP by nick translation and hybridized to normal meta-
phase chromosomes derived from mouse embryo fibroblasts. These anal-
yses were performed at Genome Systems (St. Louis, MO).
Electrophysiology
Hippocampus. The 400-m-thick slices were prepared from 5- to 29-
week-old mutant mice and littermate wild types via standard procedures,
as described previously (Conquet et al., 1994). Slices were submerged in
a medium that comprised (in mM) 124 NaCl, 3 KCl, 26 NaHCO3, 1.4
NaH2PO4, 1 MgSO4, 2 CaCl2, and 10 D-glucose (bubbled with 95%
O2/5% CO2, pH 7.4); the medium was perfused at a rate of 4 ml/min
(29–31°C). Extracellular recordings were obtained from stratum radia-
tum or stratum pyramidale of area CA1 in response to low-frequency
(0.033 Hz) stimulation of the Schaffer collateral–commissural pathway.
For each protocol one slice was used per animal; hence n values give the
number of slices per mice used. Results were analyzed via Student’s t
tests or ANOVA, with p  0.05 taken to indicate statistical significance.
Animals were genotyped by PCR and presented to the experimenter in
a randomized and blind manner.
Neocortex . Brain slice preparation and visualization of neurons in the
living slice are described previously (Stuart et al., 1993; Markram et al.,
1997). During recordings the slices were maintained at room tempera-
ture (20–24°C) in extracellular solution consisting of (in mM) 125 NaCl,
2.5 KCl, 25 glucose, 25 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, and 1 MgCl2,
pH 7.2. Whole-cell voltage recordings were performed simultaneously
from two neurons with pipettes filled with (in mM) 115 K-gluconate, 20
KCl, 4 ATP-Mg, 10 phosphocreatine, 0.3 GTP, and 10 HEPES, pH 7.3
(310 mOsm). In synaptically connected neurons a suprathreshold intra-
cellular stimulation of presynaptic pyramidal cells evoked depolarizing
EPSPs. Presynaptic pyramidal cells were stimulated with a 10 Hz train of
two to three suprathreshold current pulses. Typically, the trains were
delivered at intervals of 5–7 sec for mGluR7/ mice and at 30 sec for
mGluR7/ mice so that recovery from short-term modification was
complete, as evidenced by the lack of systematic changes in the amplitude
of the first EPSP of a train during successive trains of stimuli. For
recovery from facilitation measurements, two action potentials delayed at
variable time intervals (t) were delivered every 30 sec in both
mGluR7/ and mGluR7/ mice. Voltage traces that are shown are
averages of 50–100 sweeps. The amplitude of the first EPSP of the train
is defined as the difference between the peak of the EPSP and baseline.
For the second (or third) EPSP the amplitude is the difference between
the peak of the EPSP and the baseline measured just before the onset of
the EPSP. Stimulus delivery, data acquisition, and analyses were per-
formed with macros in IGOR (Wavemetrics, Lake Oswego, OR).
Drug administration
Pentylenetetrazole (PTZ; Metrazol, Knoll AG, Liestal, Switzerland) was
given intraperitoneally at a subthreshold dose of 40 mg/kg or at a
suprathreshold dose of either 60 (in mGluR4 wild types and mutants) or
70 mg/kg (in mGluR7 and mGluR8 wild types and mutants). A dose of
40 mg/kg PTZ induced clonic or clonic-tonic seizures in mGluR7/
mice only, whereas it failed to induce seizures that were visible behav-
iorally in mGluR4/, mGluR4/, mGluR4/, mGluR7/,
mGluR7/, mGluR8/, mGluR8/, or mGluR8/ mice. A PTZ
dose of 70 mg/kg induced clonic seizures of 5 sec duration in at least
90% of all of the mGluR mutant and wild-type mice. Anticonvulsant
drugs were given 1 hr before PTZ. Doses used in mGluR7/,
mGluR7/, and mGluR7/ mice treated with 40 mg/kg PTZ were as
follows: valproate (VPA; Depakine, Sanofi, Paris, France) (500 mg/kg,
p.o.), ethosuximide (ESM; Galenica, Berne, Switzerland) (500 mg/kg,
p.o.), clonazepam (CZP; Rivotril, Roche, Gipf-Oberfrick, Switzerland)
(0.1 mg/kg, p.o.). In the experiment in which mGluR7 mutant mice were
given 70 mg/kg PTZ (see Fig. 4, black bars), at 1 hr before PTZ the mice
received placebo (water, p.o.), 500 mg/kg VPA, 750 mg/kg ESM, or 1
mg/kg CZP. In this experiment the dosing of ESM and CZP was
increased to assure maximum chances of success for counteracting the
seizures in mGluR7/ mice. Note that a dose of 70 mg/kg PTZ is far
above threshold in mGluR7/ mice. Bicuculline (Sigma, St. Louis, MO)
was given subcutaneously at 2.5 mg/kg (mGluR7/ and mGluR7/
mice) or 3.5 mg/kg [Maus Auszucht Geigy (MAG) mice]. (R,S)-4-
phosphonophenylglycine (PPG; Tocris, Bristol, UK) was dissolved in
0.9% NaCl, pH-adjusted to 6–7, and injected intracerebroventricularly
into the mice under light Fluothane anesthesia. Injection volume was 2.5
l /mouse. Intracerebroventricular administration of PPG in 0.9% NaCl
or placebo (0.9% NaCl) occurred 15 min before PTZ was given. Doses
required to evoke seizures in 80% of anesthetized (and 0.9% NaCl
placebo injected intracerebroventricularly) wild-type (OF-1, MAG,
129OlaC57BL/6) or heterozygous mGluR4, mGluR7, or mGluR8 mu-
tant mice with different and mixed genetic backgrounds including 129Sv/
JCD-1 (mGluR4), 129OlaC57BL/6 or 129OlaBALB/c (mGluR7),
and 129Sv/JC57BL/6 (mGluR8) were 60 mg/kg (for 129CD-1) and 70
mg/kg (for all others). Concentrations and application modes are indi-
cated in the text and legends. All whole animal experiments were
approved and conducted according to the Swiss legislation and guide-
lines on animal experimentation.
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Seizure scoring
Mice were considered protected from seizures and scored as such when
neither clonic nor clonic-tonic seizures were observed within the first 10
min after PTZ treatment and within 30 min after bicuculline treatment.
After PTZ or bicuculline treatment, clonic convulsions (myoclonic jerks,
forelimb clonus) of 5 sec duration and clonic-tonic (hindlimb exten-
sion) convulsions were scored by using behavioral monitoring, as de-
scribed previously (Schmutz et al., 1990).
EEG recordings
Stainless steel screw electrodes were implanted bilaterally over the fron-
tal and parietal cortex under isoflurane/O2/N2O (0.5 l /min) anesthesia.
An indifferent electrode served as ground electrode and was positioned
at bregma F1.6/ l2.5. All screw electrodes were connected by insulated
stainless steel wiring to a four-pole socket embedded in dental cement.
The electroencephalogram (EEG) that was analyzed was the differential
between the frontal (bregma F  1.0/ l3.2) and parietal (F  3.0/ l3.2)
electrodes of the same hemisphere compared with the combined refer-
ence electrodes. Bipolar leads from the mice were recorded via cables
connected to a slipstring system, at the earliest 21 d after the operation.
The behavior of the animals, which were housed singly in wooden
observation cages measuring 32  32  40 cm, was observed over a
closed circuit TV system. The EEGs were amplified by an isolated
four-channel bipolar EEG amplifier (Spectralab EEG-2104, Kilchberg,
Switzerland), recorded on a thermorecorder (MTK95, Astromed), and
collected on a personal computer.
RESULTS
Generation of mGluR7/ mice
mGluR7/ mice were generated by homologous recombination
(Fig. 1a). They completely lacked mGluR7 mRNA (Fig. 1d–f) in
agreement with previously shown in situ hybridization results
(Masugi et al., 1999). mGluR7a (Fig. 2a–c) and mGluR7b pro-
teins (data not shown) were absent in mGluR7/ mice. Brain
mRNA expression levels for other group III mGluRs (mGluR4
and mGluR8) were unchanged (Fig. 1d). Gross histological ab-
normalities in brains of mice aged 12 weeks were not apparent,
neither in standard hematoxylin and eosin-stained sections nor
after immunohistology. The latter analysis included antibodies
specific for the group III mGluRs mGluR4a and mGluR8a, re-
spectively, as well as antibodies directed against other mGluR
subtypes (Shigemoto et al., 1997) (data not shown).
Previous observations in 6- to 8-week-old animals from our
colony also had not revealed any histological abnormalities (Ma-
sugi et al., 1999). Aging and health status of mGluR7/ mice did
not differ from mGluR7/ littermates, except for a slight reduc-
tion in body weight (mGluR7/, 25  4 gm, n 	 10 vs
mGluR7/, 31 3 gm, n	 9; age 4 months) and poor fecundity.
There was no major morbidity except for seizures in mice aged
from 10 to 12 weeks and abnormal fear and conditioned taste
aversion responses in mice aged 6–8 weeks (Masugi et al., 1999).
An epilepsy-prone phenotype of mGluR7/ mice
Spontaneous seizures were precipitated repeatedly in standard
pathogen-free (SPF) mGluR7/ mice. The seizures were ob-
served in mice aged from 10 weeks to 9 months (oldest age that
was examined), but not in 6- to 8-week-old mGluR7/ mice.
They were never observed in mGluR7/ or mGluR7/ litter-
mates, but an observer (unaware of the genotype) was able to
detect the phenotype in 17 of 20 mGluR7/ mice.
These sensory stimulus-evoked seizure episodes occurred after
cage transfer. The seizures were clonic (myoclonic jerks, forelimb
clonus) and sometimes tonic in nature. A lag phase of 3 d
generally was required before mGluR7/ mice showed renewed
susceptibility to the same type of stimulus. Whatever its chemical
nature (so far unresolved), it derived from the bedding material
and, most likely, was olfactory in nature (data not shown). Its
further characterization proved difficult because of the variability
that was seen in seizure frequency with different batches of
bedding material. Interestingly, a series of other visual, vestibular,
and olfactory sensory stimuli that were tested failed to identify
another stimulus that was evoking seizures (data not shown). In
contrast, two chemical convulsants reproducibly evoked seizures
in mGluR7/ mice at doses that were significantly below thresh-
old for mGluR7/ and mGluR7/ mice (see below).
The epilepsy-prone phenotypes appeared in mGluR7/ mice
derived from two independently targeted ES cell clones and in
mutants with different genetic backgrounds [in 129OlaC57BL/6
hybrid mice and in mice back-crossed for several generations on
either C57BL/6 (F3–F14) or BALB/c (F6)].
The mouse mGluR7 gene was localized to chromosome 6E1
(Fig. 2f), and 70 kb of 129Ola mouse genomic DNA was se-
quenced around the disrupted mGluR7 exon (S. D. McDonald, S.
Goff, H. van der Putten, unpublished results). Neither procedure
provided links to genes (other than the mGluR7 gene) known for
predisposing to epilepsy (Allen and Walsh, 1996; McNamara and
Puranam, 1998; Bate and Gardiner, 1999; Frankel, 1999), strongly
Figure 2. Lack of mGluR7 protein in mGluR7/ mice. a–d, Immuno-
cytochemical analysis comparing reactivity of the mGluR7a-specific an-
tibody in a brain section of a mGluR7/ mouse (a and hippocampus
shown enlarged in c) and lack of reactivity in mGluR7/ mouse brain (b
and hippocampus shown enlarged in d). Scale bars: 2 mm (white horizontal
line in a, b) and 400 m (black horizontal line in c, d), respectively. e,
Immunoblot that uses a polyclonal rabbit mGluR7a-specific antibody
(Shigemoto et al., 1996, 1997; Kinoshita et al., 1998) of homogenates of
mGluR7/ (wt) and mGluR7/ (ko) brain regions, including cerebel-
lum [lanes 1, 4; serving also as a negative control because this brain region
contains undetectable levels of mGluR7a (Kinoshita et al., 1998)], hip-
pocampus (lanes 2, 5), and the other combined brain regions without
hippocampus and cerebellum (lanes 3, 6 ). The arrow indicates the posi-
tion in the gel of the bulk of mGluR7a protein. f, Localization of the
mouse mGluR7 gene to chromosome 6E1 by fluorescent in situ hybrid-
ization (FISH). White arrows indicate the position of the fluorescent
signal on chromosome 6.
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suggesting that it is the homozygous mutant mGluR7 genotype
that determines the epilepsy-prone phenotype in these mice.
mGluR7/ mice have a lower seizure threshold
for convulsants
The initial discovery of sensory stimulus-evoked seizures was not
suitable as an experimental paradigm for further studies, first
because of the unresolved chemical nature of the stimulus and
second because of the great degree of variability in seizure
incidence of mGluR7/ mice housed in different environments.
Nevertheless, our initial findings in SPF-housed mGluR7/
mice suggested a significantly reduced threshold for seizures in
these mice. Our failure to identify another defined sensory stim-
ulus that could provoke seizures reproducibly in mGluR7/
mice prompted us to test subconvulsant doses of two drugs,
pentylenetetrazole (PTZ) and bicuculline.
When administered intraperitoneally at a dose of 40 mg/kg,
PTZ is generally subthreshold for inducing clonic seizures in
control animals. In mice 12 weeks and older, it induced seizures
in 1 of 40 mGluR7/ and in 4 of 49 mGluR7/ mice. In
contrast, it evoked seizures in the majority of mGluR7/ litter-
mate mice (43 of 58; 74%) (Fig. 3a). Note that all of these mice
were aged 10 weeks or older before testing to assure development
of the epilepsy-prone phenotype in mGluR7/ mice. The PTZ-
evoked seizures in mGluR7/ mice were frequently both clonic
and tonic in nature and were followed by death (
50% of the
mice). For comparison, in mGluR7/ and mGluR7/ mice, 70
mg/kg PTZ was required to produce seizures that consistently
were generally only clonic in nature.
In mice aged 6 weeks the PTZ (40 mg/kg) failed to evoke
seizures in a statistically significant manner (Kruskal–Wallis one-
way ANOVA on ranks, p 	 0.407). In only 1 of 10 mGluR7/
mice were the seizures observed. When this mouse was elimi-
nated from the group and the others were retested (40 mg/kg
PTZ) at age 10 weeks, six of nine mGluR7/ mice showed
clonic seizures. In parallel and at both ages only one mouse of two
groups of n	 10 mGluR7/ mice (MAG; parental strains, NIH
and Maus Inzucht Geigy) and no mGluR7/ mice showed
seizures ( p 	 0.003, Kruskal–Wallis one-way ANOVA on ranks
revealed a significant difference among the genotypes; p 	 0.023,
Mann–Whitney rank–sum test for / vs /).
Five different groups (n 	 9–10 per group and genotype) of
Figure 3. Increased PTZ susceptibility of mGluR7/ mice to convul-
sant drugs. a, Age-dependent development of a seizure-prone phenotype
in mGluR7/ mice (129OlaC57BL/6 and 129OlaBALB/c mixed
strain backgrounds). Groups of 8–10 mGluR7/, mGluR7/, and
mGluR7/ mice aged 6, 10, and older than 12 weeks (this last group
included a group of nine mGluR7/ and nine mGluR7/ mice aged 36
weeks) were given PTZ (40 mg/kg, i.p.). Seizures (tonic in mGluR7/
and mGluR7/ mice, and either tonic or tonic-clonic in mGluR7/
mice) were scored behaviorally. Animals were considered protected from
the convulsant effect of PTZ when neither clonic nor clonic-tonic convul-
sions were observed within the first 10 min after PTZ (Schmutz et al.,
1990). The numbers above the bars correspond to the number of mice
tested in an age group. The group aged 
12 weeks included groups of
mGluR7/, mGluR7/, and mGluR7/ mice aged 12–14, 14–18, and
22–24 weeks, respectively. It also included one group aged 36 weeks, of
nine mGluR7/ and nine mGluR7/ mice, but no mGluR7/ mice.
Of these mice, one of nine mGluR7/ and eight of nine mGluR7/
showed seizures. Confidence limits in the groups of 
12 weeks were
10% for the mGluR7/ groups and15% for the mGluR7/ groups.
4
b, Electrographic seizures in mGluR7/ mice. EEGs recorded for 1
week and for 24 hr continuously in freely moving mGluR7/ and
mGluR7/ mice (each group n 	 4, aged 16–20 weeks) revealed no
spontaneous epileptiform activity (data not shown). After the 1 week of
recording the same mice were given 40 mg/kg PTZ, and the seizures were
recorded by behavior as well as by electroencephalography. For each
genotype group two representative EEG recordings from two different
individuals are shown, starting at 210 sec after PTZ injection. The top two
traces are from two different mGluR7/ mice; the bottom two traces are
from two different mGluR7/ mice. The first mGluR7/ mouse (top
trace) had tonic-clonic seizures; the second mGluR7/ mouse (second
trace from top) had clonic seizures manifested behaviorally as body jerks
(arrowheads in EEG). None of the mGluR7/ mice (bottom two traces)
showed epileptiform activity. Time scale is shown in seconds, and ampli-
tude is in microvolts. c, Increased susceptibility to seizures for the
GABAA receptor antagonist bicuculline, as shown by comparing two
groups of 10 mGluR7/ and mGluR7/ mice (aged 14–16 weeks) that
were given 2.5 mg/kg bicuculline. Seizures were scored behaviorally.
Plotted is the time in minutes for individual animals to develop clonic
seizures. Observation time was 30 min after drug application, and mice
plotted at this value were without seizures.
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mGluR7/, mGluR7/, and mGluR7/ mice were tested at
ages 12–36 weeks, and the overall results are shown (Fig. 3a). One
of 40 (2.5%) mGluR7/ and 4 of 49 (8%) mGluR7/ mice
showed seizures (clonic only). In contrast, 37 of 49 (75%)
mGluR7/ mice showed clonic seizures that often (in 
60% of
these mice) progressed to tonic seizures. Often, mGluR7/ mice
with tonic seizures died. Statistical significance for the results in
the groups aged 
12 weeks is given by pairwise comparison of
the genotype groups with the Mann–Whitney rank–sum test
( p 	  0.001 for the / vs / and the / vs / groups;
p 
 0.05 and no statistical significance when comparing / and
/ groups). At age 36 weeks, differences in PTZ sensitivity
remained statistically significant ( p 	 0.002, Mann–Whitney
rank–sum test; comparison of a single group of nine mGluR7/
and nine mGluR7/ mice).
Spontaneous epileptiform activity was not detected during 1
week of continuous (24 hr/d) EEG recordings by using bilaterally
implanted frontal and parietal electrodes in mGluR7/ (n 	 4)
and mGluR7/ (n	 4) mice. A subsequent injection of PTZ (40
mg/kg, i.p.) rapidly triggered epileptiform discharges and seizure
manifestations that were specific to the mGluR7/ mice. The
same dose of PTZ injected into the mGluR7/ mice triggered
no detectable discharges (Fig. 3b), indicating a significantly re-
duced threshold for PTZ-induced discharges and seizures in the
mGluR7/ mice.
Susceptibility to seizures also was increased for the competitive
GABAA receptor antagonist bicuculline. Two groups of 10
mGluR7/ and mGluR7/ mice (aged 14–16 weeks) were
given 2.5 mg/kg bicuculline subcutaneously and were observed
for 30 min. The latency to first seizure was plotted (Fig. 3c) for
individual animals showing clonic seizures. Mice plotted at the 30
min value were without seizures. The median (horizontal bar in
bold) for each group was 4 min (mGluR7/, 25% at 4 min and
75% at 5 min) versus 26 min (mGluR7/, 25% at 8 min and 75%
at 30 min), respectively (Mann–Whitney rank–sum test, p 	
0.003). For reference, nine of nine mGluR7/ MAG mice
treated with the same lot, and for MAG mice a standard suprath-
reshold dose of 3.5 mg/kg bicuculline, showed clonic seizures
with a mean onset time of 3.2 min (data not shown).
Effects of standard anticonvulsant drugs
Three widely used mechanistically different antiepileptic drugs
(White, 1997), ethosuximide (ESM), clonazepam (CZP), and
valproate (VPA), were tested in mGluR7/ mice for protection
from PTZ-evoked seizures (Fig. 4).
First (Fig. 4a,b, gray bars), three groups of 10 mGluR7/ and
10 mGluR7/ mice (all aged 14–20 weeks) received pretreat-
ment (1 hr before 40 mg/kg PTZ, i.p.) with an antiepileptic drug
(CZP, 0.1 mg/kg, p.o.; ESM, 500 mg/kg, p.o.; VPA, 500 mg/kg,
p.o.). In parallel, another group of 10 mGluR7/ and 10
mGluR7/ mice and, in addition, 10 mGluR7/ wild-type
(MAG) mice received a placebo (Methocel as reference for ESM
and CZP; water compared with VPA). At 1 hr after placebo or
anticonvulsant drug treatment all of the mice were given PTZ (40
mg/kg, i.p.). PTZ induced seizures in 60–90% of each of the
placebo-treated mGluR7/ groups (n 	 3  10), but not in any
of the placebo-treated mGluR7/ (n 	 3  10) or mGluR7/
(MAG; n 	 3  10) mice. ESM, CZP, and VPA protected 100%
of the mGluR7/ mice (n 	 10 per group and compound) from
PTZ-induced seizures (statistical significance for each drug-
treated versus placebo group is given by p 0.05, Mann–Whitney
rank–sum test).
All three anticonvulsant drugs also provided protection in
mGluR7/ mice when challenged with 70 mg/kg PTZ (Fig.
4a,b, black bars), a dose that evoked clonic seizures in at least
90% all mGluR7/ (Fig. 4b) and mGluR7/ mice (data not
shown). In this experiment we increased the dose of ESM (to 750
instead of 500 mg/kg) and CZP (to 1 mg/kg instead of 0.1
mg/kg). VPA dosing (500 mg/kg) was not increased, because this
can cause lethality in mice. Given that all three anticonvulsants
protected mGluR7/ mice from either 40 or 70 mg/kg PTZ-
Figure 4. The actions of three standard anticonvulsants are unimpaired
in mGluR7/ mice. a, b, Plotted is the percentage of mice with seizures,
scored behaviorally, for a period of 10 min in response to PTZ (40 or 70
mg/kg) given intraperitoneally. The number above each bar indicates the
group size. The gray bars represent groups of mice given 40 mg/kg PTZ
that were pretreated 1 hr before PTZ with either placebo (Methocel in
two groups of n 	 10 per genotype and as reference for ESM and CZP;
water was the placebo in one group of n	 10 per genotype and compared
with VPA) or anticonvulsant (0.1 mg/kg CZP, p.o.; 500 mg/kg ESM, p.o.;
or 500 mg/kg VPA, p.o.). The black bars in a and b represent groups of
10 mice per genotype that had received PTZ (70 mg/kg, i.p). At 1 hr
before PTZ all of the mice in a group had received the placebo (water,
p.o.), CZP (1 mg/kg, p.o.), ESM (750 mg/kg, p.o.), or ESM (500 mg/kg).
Unlike in mGluR7/ mice (b), the 40 mg/kg PTZ dose is below
threshold for inducing seizures in mGluR7/ (a) and wild types
(mGluR7/ mice; data not shown). Therefore, mGluR7/ mice dis-
played no seizures, regardless of pretreatment with placebo or anticon-
vulsant. In contrast, 70% of all mGluR7/ mice showed clonic or
clonic-tonic seizures when given placebo (b). The injection of 70 mg/kg
PTZ evoked seizures (clonic in mGluR7/ and mGluR7/ mice; clonic
or clonic-tonic in mGluR7/ mice) in at least 90% of all placebo-treated
mice, regardless of their mGluR7 genotype. CZP, ESM, and VPA fully
protected from PTZ-induced clonic seizures in mGluR7/ (black bars in
a) and mGluR7/ mice (data not shown) as well as from PTZ-induced
clonic or clonic-tonic seizures in mGluR7/ mice.
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induced seizures, we conclude that mGluR7 receptors do not
contribute significantly to mechanisms underlying the action of
these antiepileptics.
Anticonvulsant effects of PPG are diminished greatly in
mGluR7/ mice
The group III mGluR selective agonist PPG has shown potent
and sustained anticonvulsant actions in several rodent models of
epilepsy (Chapman et al., 1999; Gasparini et al., 1999). Therefore,
we compared its anticonvulsant action against PTZ-evoked sei-
zures in mGluR7/ mice and two other mGluR group III
mutant mice, the mGluR4/ and mGluR8/ mutants. All of
the mice used in these experiments were aged from 12 to 20
weeks before testing to allow for development of the seizure-
prone phenotype in the mGluR7/ mice. Also, we tested dif-
ferent doses of PTZ to determine, in each of the strain back-
grounds of the different mutants, a dose that evoked clonic
convulsions in 80% or more of the mice under the experimental
conditions that were used, i.e., light Fluothane anesthesia, intra-
cerebroventricular injection of placebo (0.9% NaCl), followed 15
min later by intraperitoneal injection of PTZ. Determining these
experimental conditions was necessary because PPG is not active
when given systemically (Gasparini et al., 1999), and, when given
intracerebroventricularly, it requires brief anesthesia that in-
creases PTZ thresholds (data not shown). In addition, PTZ
thresholds depend on multiple chromosomal loci that differ be-
tween mouse strains (Kosobud et al., 1992; Ferraro et al., 1999),
and mGluR4/, mGluR7/, and mGluR8/ mutant mice
have mixed and different genetic contributions from a number of
strains. Accordingly, the PTZ doses required under our experi-
mental conditions were 60 mg/kg in mGluR4 mutants (129Sv/
JCD1) and 70 mg/kg in mGluR7 [129OlaC57BL/6 and
(129OlaC57BL/6)BALB/c] and mGluR8 [(129C57BL/
6)C57BL/6] mutants.
Next, dose responses for PPG (see Gasparini et al., 1999) (data
not shown) in the different heterozygous mGluR mutant mice
revealed that 634 nmol intracerebroventricularly (2.2 mg/kg)
could protect 70% of the different heterozygous mutant mice
from seizures induced by PTZ. This protective effect of PPG was
reduced dramatically in mGluR7/, but not in mGluR4/ and
mGluR8/, mice (Fig. 5). The loss of the anticonvulsant activity
of PPG in mGluR7/ mice treated with 70 mg/kg PTZ was
specific to PPG because CZP, ESM, and VPA provided complete
protection in both mGluR7/ and mGluR7/ mice challenged
with this dose of PTZ (Fig. 4a,b; 70 mg/kg PTZ dose results are
represented by black bars in the histograms).
Altered excitability in hippocampal slices
Because of similarities between seizures observed in mGluR7/
mice and those known to involve limbic systems, we examined
electrophysiological responses in hippocampal slices. We focused
primarily on synaptic transmission in the CA1 region because
CA3-derived Schaffer collateral–commissural terminals are rich
in mGluR7a (Shigemoto et al., 1996, 1997) (Fig. 2c) and CA3 is
a major trigger region for discharge activity that can propagate to
CA1 and beyond in different models of epileptic discharge (Wong
and Traub, 1983; Barbarosie and Avoli, 1997). Input–output
curves relating the initial slope of the field EPSP to either stim-
ulus intensity or presynaptic fiber volley amplitude revealed no
significant differences between mGluR7/ and mGluR7/
mice (Fig. 6a,b). Paired pulse facilitation was also similar between
groups. For example, with an interpulse interval of 50 msec the
facilitation ratios in CA1 were 1.45 0.04 (n	 9) and 1.49 0.03
(n 	 9), respectively.
Next, we determined whether hippocampal slices from
mGluR7/ mice were more excitable when the stimulus inten-
sity was increased to evoke a population spike and activate
GABAergic synapses polysynaptically (Fig. 6c,d). In the absence
of PTZ a very small secondary population spike was apparent in
8 of 11 slices from null mice (0.067  0.020 of the first population
spike) but only in 1 of 10 slices from controls (0.009 0.011 of the
first population spike; Student’s t test, p  0.05). Thus, slices
prepared from mGluR7/ mice were slightly more excitable
under control conditions.
Given the lower seizure threshold of mGluR7/ mice to PTZ,
we examined the effects of PTZ on synaptic transmission in CA1.
PTZ caused a reduction in synaptic inhibition, manifest as a
concentration-dependent appearance of multiple population
spikes in both mGluR7/ and wild-type mice (Fig. 6c,d). The
effect was such that differences in excitability between
mGluR7/ and wild-type littermates, observed in the absence of
PTZ, were no longer evident when higher concentrations of PTZ
(1–4 mM) were used.
Figure 5. Greatly reduced anticonvulsant action of PPG in mGluR7/
mice. Shown are the protective effects of 634 nmol of PPG intracerebrov-
entricularly (black bars) versus 0.9% NaCl ( gray bars) in mGluR7/
mice (/) and the different mGluR/ and mGluR/ mutant mice as
indicated by the numbers 4, 7, and 8 on the horizontal axis (all mice aged
12 weeks). PPG was given intracerebroventricularly 15 min before the
intraperitoneal injection of PTZ [60 mg/kg in mGluR4 mutants; 70
mg/kg in all wild types (/) and other mGluR mutants]. Seizures were
scored behaviorally for a period of 10 min (Schmutz et al., 1990). The
numbers above the bars indicate the number of mice per group. The
protective effects of PPG versus NaCl were 78% (22 of 28) versus 6% (1
of 17) in mice with one mutant mGluR7 allele and 26% (6 of 23) versus
0% (0 of 20) in mice with two mutant mGluR7 alleles. Unlike a compar-
ison of the protective effect of PPG between mGluR7/ and
mGluR7/ mice, there were no statistically significant differences in the
protective action of PPG when mGluR4/, mGluR4/, mGluR8/,
and mGluR8/ groups were compared (all p 
 0.05). Confidence limits
for the groups n 
 10 were 10%. For PPG versus NaCl comparisons in
all groups, p values were 0.001 (Kruskal–Wallis one-way ANOVA on
ranks, Dunn’s test). Other values were mGluR7/ versus mGluR7/
(wild type), p 	 0.004; mGluR7/ versus mGluR4/, p  0.001;
mGluR7/ versus mGluR8/, p 	 0.014 (Mann–Whitney rank–sum
tests).
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Altered frequency-dependent facilitation in
mGluR7/ mice
To investigate mechanisms that might underlie the changes in
excitability, we turned to a different slice preparation and studied
transmission between synaptically coupled pyramidal neurons
and bitufted interneurons in layer 2/3 of the neocortex. This
synapse contains a high density of presynaptic mGluR receptors,
including mGluR7 (Shigemoto et al., 1996), and it demonstrates
frequency-dependent facilitation (Reyes et al., 1998), which is
believed to arise from the elevation of Ca2 at the presynaptic
release site (Zucker, 1994; Fisher et al., 1997; Rozov et al., 2001).
As seen in the hippocampus (see paired pulse data in previous
section), facilitation in response to brief trains of two or three
action potentials (at 10 Hz in this preparation) was similar in
mGluR7/ and mGluR7/ mice, provided that the intersweep
interval time was sufficiently long (Fig. 7a; in both cases inter-
sweep interval was 30 sec). However, a marked difference was
observed among mice when recovery from facilitation was stud-
ied. In one set of experiments paired pulses were delivered with
a fixed interpulse interval of 100 msec, but the interval between
Figure 6. Increased excitability in the CA1 region of hippocampal slices
from mGluR7/ mice. a, Plotted is the slope of the field EPSP, recorded
in stratum radiatum, versus relative stimulus strength, expressed as a
function of the threshold intensity (i.e., the intensity at which a response
is just detectable in single records) for mGluR7/ and mGluR7/ mice.
The traces are averages of successive responses from a typical
mGluR7/ mouse at the times indicated (1–3); the input–output curves
show no significant difference in excitatory synaptic transmission between
wild-type (n	 14) and null mice (n	 12). b, Input–output curve, relating
the slope of the field EPSP to the presynaptic fiber volley amplitude. c,
Examples of somatic field recordings from wild-type (1–3) and
mGluR7/ mice (4–6 ) to illustrate the effects of increasing concentra-
tions of PTZ. The insets are a magnification (2.5) of the windows shown
in c1 and c4 to illustrate the generation of multiple population spikes on
a faster time base. Field potentials were recorded from stratum pyrami-
dale and input–output curves that were constructed. Then the stimulus
intensity was set at that which produced a first population spike of 30%
of the maximum, and PTZ was applied sequentially in increasing con-
centrations. d, Pooled data for 10 wild-type and 11 mGluR7/ mice
(aged between 8 and 29 weeks) of the amplitude of the second population
spike, expressed as a function of the primary population spike, versus
PTZ concentration. Open symbols, mGluR7/ mice; filled symbols, lit-
termate wild types, throughout.
Figure 7. Altered recovery from paired pulse facilitation in mGluR7/
mice. Simultaneous whole-cell paired recordings from synaptically con-
nected pyramidal and bitufted neurons in layer 2/3 of mGluR7/ (n	 9)
and mGluR7/ (n 	 7) mice (P14; neocortex). a, Averaged EPSPs (n 	
50–100) recorded from bitufted neurons of mGluR7/ and mGluR7/
mice in response to a train of three action potentials evoked in a project-
ing pyramidal neuron at 10 Hz. Time intervals between trains (intersweep
intervals) were 30 sec in both cases. b, Averaged EPSPs of 50–100 sweeps
recorded from bitufted neurons in response to two action potentials that
were evoked in pyramidal neurons with a 100 msec time interval. The
difference between the lef t and right traces is the intersweep interval (time
between subsequent pairs of action potentials). For the lef t traces it was 20
sec, and for the right traces it was 7 sec, as indicated above the traces. The
top traces in each box represent recordings from mGluR7/ mice, and
the bottom traces are from mGluR7/ mice. For each genotype the
representative recordings that are shown (i.e., averaged EPSPs of 50–100
sweeps) are from the same bitufted neuron. c, Time course of recovery
from facilitation measured in bitufted neurons. The ratios of the mean
EPSP amplitudes (EPSP2/EPSP1) were plotted against t.
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paired pulses (intersweep interval) was varied between 5 and 30
sec (Fig. 7b). Averaged EPSPs recorded from the same bitufted
neuron (see lef t trace in a) in a mGluR7/ mouse in response to
a train (10 Hz) of two action potentials delivered at 20 sec (left)
and 7 sec (right) intersweep intervals shows that the amplitude of
the first EPSP (EPSP1) and the paired pulse facilitation ratio
(EPSP2/EPSP1) were similar at 20 and 7 sec intersweep interval
times. In this mouse the EPSP1 amplitudes were 0.46 and 0.49
mV, and EPSP2/EPSP1 ratios were 2.24 and 2.12 at the 20 and 7
sec intersweep intervals, respectively. In the mGluR7/ mouse
(bottom traces) the EPSP1 amplitude increased from 0.39 mV at
the 20 sec intersweep interval to 0.75 mV at the 7 sec intersweep
interval, and the EPSP2/EPSP1 ratio decreased from 2.61 to 1.28
at the 20 and 7 sec intersweep intervals, respectively. Overall, in
this set of experiments the EPSP1 amplitudes with the 7 sec
intersweep interval were 100  12% of those measured with 20
sec interval, and the EPSP2/EPSP1 ratios were 2.51  0.28 and
2.56  0.47 at the 20 and 7 sec intersweep intervals, respectively,
in mGluR7/ mice (n 	 4). In the mGluR7/ group the
EPSP1 amplitudes with the 7 sec intersweep interval were 59.7 
28.3% larger than those recorded at the 20 sec interval. EPSP2/
EPSP1 ratios decreased from 2.87 0.88 to 1.27 0.03 for 20 and
7 sec, respectively. In summary, in mGluR7/ mice the facilita-
tion recovered within 5–7 sec, as observed previously with rats
(Reyes et al., 1998). In contrast, in mGluR7/ mice full recovery
from facilitation required 20–30 sec.
In a separate set of experiments the time course of recovery
from facilitation was calculated by using a repeated paired pulse
protocol. Every 30 sec a train of two action potentials (indicated
as EPSP1 and EPSP2) was evoked. One of several different time
intervals was chosen (t 	 0.1, 1, 2, 5, and 10 sec, respectively)
between action potentials 1 and 2, and 50–100 individual sweeps
were averaged for each t. The intersweep intervals thus were
kept constant at 30 sec in all of these experiments to allow the
facilitation to recover in mGluR7/ mice also. The plot shows
the summarized results of delivering paired pulses with the dif-
ferent interpulse intervals. In mGluR7/ mice the recovery
from facilitation was evident by 2 sec, whereas even after 10 sec
the recovery in mGluR7/ mice was still incomplete (Fig. 7c).
DISCUSSION
Epilepsy-prone phenotype of mGluR7/ mice, but not
other mGluR-deficient mice
In contrast to gene ablations of mGluR 1, 2, 4, 5, 6, and 8,
respectively (Aiba et al., 1994; Conquet et al., 1994; Masu et al.,
1995; Pekhletski et al., 1996; Yokoi et al., 1996; Lu et al., 1997;
Duvoisin and Zhang, unpublished observations), gene disruption
of mGluR7 predisposes to epilepsy. This points toward an im-
portant role of this particular group III mGluR in regulating the
balance between excitatory and inhibitory transmission. The re-
duced thresholds for PTZ, bicuculline, and sensory stimulus-
evoked seizures in mGluR7/ mice are acute results of the
absence in adult tissue of a single or both isoforms of mGluR7
receptors. Alternatively, they are a consequence of absence of the
receptor throughout development. Addressing these questions
awaits the development of mGluR7-specific antagonists, condi-
tional knock-outs, or mGluR7/ mice in which receptor expres-
sion is reconstituted in the adult.
In either case the mGluR7/ mouse provides an interesting
model of epilepsy, given that (1) the seizure susceptibility phe-
notype develops gradually, (2) they are uniquely associated with
an ablation of this and no other mGluR subtype, and (3) when
evoked by PTZ, the seizures are responsive to representatives of
three major classes of anticonvulsants [ethosuximide is thought to
act via modulation of Na and Ca2 channels (Coulter et al.,
1989); clonazepam, a benzodiazepine, increases the frequency of
GABAA receptor chloride channel opening and is especially
potent in preventing PTZ-induced seizures (Henriksen, 1998);
valproate is a drug with a broad preclinical and clinical profile but
is poorly understood mechanistically (McLean and Macdonald,
1986; Kelly et al., 1990; Rogawski and Porter, 1990; Van Erp et
al., 1990; Zona and Avoli, 1990)]. Apparently, mGluR7 does not
contribute significantly to mechanisms underlying the actions of
these antiepileptics.
In contrast, mGluR7 appears to be an important mediator of a
mechanistically different (and potentially clinically viable) anti-
convulsant principle, namely, the activation of group III mGluRs.
This was shown here by using the group III mGluR selective
agonist PPG, which proved effective against PTZ-induced sei-
zures in mGluR4/, mGluR8/, and mGluR7/, but not
mGluR7/, mice under experimental conditions in which PTZ
evoked primarily clonic seizures. These findings are somewhat
surprising, because PPG is least potent on mGluR7 of all of the
human and rat recombinant group III mGluRs for the inhibition
of forskolin-stimulated cAMP accumulation in mammalian cells
(Nakajima et al., 1993; Okamoto et al., 1994; Conn and Pin, 1997;
Gasparini et al., 1999). PPG also is anticonvulsant against sound-
induced seizures in DBA/2 mice and genetically epilepsy-prone
rats (Chapman et al., 1999) in the mouse maximal electroshock
model (Gasparini et al., 1999) and in the mouse PTZ model (Fig.
5). Unlike L-AP4 and L-SOP, PPG lacks proconvulsant activity,
and its anticonvulsant effects last much longer than those of
L-AP4 or L-SOP (Chapman et al., 1999; Gasparini et al., 1999).
However, PPG is not active when given systemically, and the
compound has sedative effects (Chapman et al., 1999; our unpub-
lished results). Therefore, novel compounds are needed to eval-
uate the potential of group III and, in particular, mGluR7-
selective drugs for treating epilepsy and/or other disorders
(Masugi et al., 1999). A recent finding that further strengthens a
role for mGluR7 receptors in epilepsy is its selective upregulation
in the inferior colliculus of genetically epilepsy-prone (GEP) rats.
This was shown to be associated with a prolonged anticonvulsant
effect of intracollicular administrated L-SOP against sound-
induced seizures in GEP rats (Yip et al., 2001).
One very limited gene polymorphism study in patients (Good-
win et al., 2000) could not provide a link between the mGluR7
gene and epilepsy. This also applies to other group III mGluRs.
However, the mGluR7 gene spans 600 kb (http://www.ncbi.nlm.
nih.gov/AceView/acegquery.cgi?db	300&ORG	hs&term	GM
M7), and more detailed studies need to be performed by using a
large number of single nucleotide polymorphisms across the locus
before any firm conclusions can be drawn regarding linkage to
disease in human.
Interestingly, mGluR4/ compared with mGluR4/ mutant
mice showed a differential resistance to absence-like seizures
induced by 30 mg/kg PTZ (Snead et al., 2000). This finding seems
to support a facilitating role of mGluR4 in absence-like seizures.
At higher doses PTZ (40–60 mg/kg) evoked clonic convulsions
and showed no difference in susceptibility between wild-type and
mGluR4/ mutant mice (Snead et al., 2000). PTZ injections (60
mg/kg) in mGluR4/ mice under our and different experimen-
tal conditions confirmed this. We failed to reveal a role for
mGluR4 in mediating the anticonvulsant action of PPG in our
PTZ paradigm, but another potent mGluR4 agonist has been
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shown to increase the latency of seizure onset in a different
PTZ-induced tonic seizure paradigm (Thomsen and Dalby,
1998). Therefore, dependent on the seizure paradigm that is
used, the role of particular group III mGluRs may differ.
This hypothesis is tempting, given findings in neuroprotection
experiments. When we used different magnitudes of a toxic
(NMDA) insult, low doses of PPG substantially reduced toxicity
in mGluR4/ mice, but not in mGluR4/ mice, whereas higher
doses were protective in both genotypes, suggesting that another
receptor might play a more important role in protection at higher
doses (Bruno et al., 2000).
Potential mechanisms underlying the
epileptic phenotype
The very small excitability changes detected in the untreated
mGluR7/ hippocampal slices are consistent and correlate well
with the absence of seizures in the mGluR7/ mice in vivo
under normal circumstances. The weak epileptogenic effects seen
in mGluR7/ hippocampal slices with a subthreshold concen-
tration of PTZ (for control slices) are consistent with the in-
creased seizure susceptibility for PTZ in the mGluR7/ mice in
vivo. The lack of a difference between mGluR7/ and their
wild-type littermates in the excitability in slices exposed to PTZ
and, in particular, at higher concentrations of PTZ is suggestive
of a common expression mechanism, namely, a net reduction in
GABAergic synaptic inhibition, for the two epileptogenic situa-
tions (absence of mGluR7 and presence of PTZ).
Recovery from facilitation reflects the restoration of presynap-
tic Ca2 levels by extrusion while synapses are not active
(Zucker, 1994; Fisher et al., 1997). Our results in the paired
stimulus paradigms (Fig. 7) are consistent with the hypothesis
that deletion of mGluR7 affects a (slow) component involved in
presynaptic Ca2 homeostasis. Resolving the underlying molec-
ular mechanism remains a challenge, not only because of the
multiple mechanisms implicated in presynaptic Ca2 regulation
(Na–Ca 2 exchange, uptake in mitochondria, the plasma mem-
brane Ca2 ATPase) [see Zenisek and Matthews (2000) and
references therein] but also because mGluR7 has been linked to
multiple effector pathways (Saugstad et al., 1996; Nakajima et al.,
1999; O’Connor et al., 1999; Perroy et al., 2000). Regardless of
which exact molecular mechanism will prove operational, a de-
layed recovery from facilitation as observed in mGluR7/ slices
may account, at least in part, for an epilepsy-prone phenotype,
given that such alterations share some features that are observed
when (presynaptic) K channels are blocked by convulsant drugs
(see, for example, Juhng et al., 1999). The mGluR7-deficient
mouse adds to a large and growing list of novel models of epilepsy
as a result of gene ablation, recently also including mice that lack
the metabotropic receptor for GABA (Prosser et al., 2001;
Schuler et al., 2001). Its uniqueness lies in the fact (1) that only
few cases have been reported in which the epileptic phenotype is
associated and/or caused by a specific presynaptic defect (such as
synapsin deficiency; Rosahl et al., 1995) and (2) that no other
mGluR gene ablation (mGluR1, 2, 4, 5, and 8) has resulted in an
epileptic phenotype despite the fact that two of these receptors
(mGluR4 and 8) have a strikingly similar presynaptic location.
Given that mGluR4, mGluR7, and mGluR8 modulate different
presynaptic parameters and show differential expression patterns
(Shigemoto et al., 1997), these receptors might serve as distinct
frequency-dependent synaptic transmission filters that accommo-
date fine tuning and information transfer under normal homeo-
static and pathological conditions (for review, see Thomson,
2000). Dissecting the molecular signaling mechanisms underlying
mGluR7 and its frequency-dependent regulation of neurotrans-
mission may shed light on why this receptor might have potential
as a drug target in epilepsy and/or other indications (Masugi et
al., 1999).
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